Replies to post #5114 on COSCIENS Biopharma Inc (CSCI)

[~ Blue ~]

AEZS ~ key developments: Data and Safety Monitoring Board recommends continuation of ZoptEC Phase 3 study of zoptarelin doxorubicin; patient enrollment completed; second interim results expected in early October 2015

Macrilen™ confirmatory Phase 3 study initiated

Saizen® co-promotion agreement concluded; promotional activities launched on July 27, subsequent to quarter-end

Global optimization program successfully completed; significant reduction of expenses at Frankfurt office through lease renegotiation